The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion

British Journal of Dermatology

Volumn 139, Issue 6, 1998, Pages 992-996

  Mrowietz, U ^a   Graeber, M ^b   Brautigam M ^c   Thurston, M ^b   Wagenaar, A ^b   Weidinger, G ^c   Christophers, E ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Clinical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; PIMECROLIMUS; PLACEBO; TOLNAFTATE;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0032406844     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02554.x     Document Type: Article

References (15)

1. Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992; 98: 851-5.
2. Rappersberger K, Meingassner JG, Fialla R et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996; 106: 701-10.
3. Meingassner JG, Grassberger M, Fahrngruber H et al. A novel anti-inflammatory drug. SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-76.
4. Christophers E, Henseler T. Psoriasis type I and type II as subtypes of nonpustular psoriasis. In: Psoriasis, 2nd edn (Roenigk HH, Maibach H, eds). New York: Marcel Dekker, 1990: 15-21.
5. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996; 110: 199-206.
6. Christophers E, Mrowietz U. The inflammatory infiltrate in psoriasis. Clin Dermatol 1995; 13: 131-5.
7. Christophers E, Parzefall R, Braun-Falco O. Initial events in psoriasis: quantitative assessment. Br J Dermatol 1973; 89: 327-54.
8. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985; 277: 352-8.
9. Kragballe K, Fogh K, Sogaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Acta Derm Venereol (Stockh) 1991; 71: 475-8.
10. Ellis CN, Gorsulowski DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1985; 256: 3110-16.
11. Mrowietz U, Färber L, Henneicke-von Zepelin HH et al. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis, results of a multicenter study. J Am Acad Dermatol 1995; 33: 470-5.
12. The European FK. 505 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996; 132: 419-23.
13. Zug KA, Littenberg B, Baughman RD et al. Assessing the preferences of patients with psoriasis: a quantitative, utility approach. Arch Dermatol 1995; 131: 561-8.
14. Grassberger M, Meingassner J, Stütz A et al. Ascomycins. In: Psoriasis, 3rd edn (Roenigk HH, Maibach HI, eds). New York: Marcel Dekker, 1998: 769-779.
15. Baumruker T, Bevec D, Kalthoff F et al. SDZ ASM 981, a novel anti-inflammatory macrolactam: pharmacological activities in vitro. Australas J Dermatol 1997; 38 (Suppl. 2): 285.